NCT02169765Unknown3 期
Hepatic Resection Versus Radiofrequency Ablation for Early-stage Hepatocellular Carcinoma: a Randomized Controlled Trial
Guangxi Medical University1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2020年8月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Overall survivals
研究概览
简要总结
Hepatocellular carcinoma (HCC) is the third leading death cancer in the world. It is important to explore a safe and effective therapy for early-stage HCC. Previous studies reported that radiofrequency ablation (RFA) has higher efficacy and is associated with fewer complications and shorter hospital stays than hepatic resection (HR) for early-stage HCC. However, meta-analysis and systematic review found that RFA is associated with higher recurrence rate and lower long-term overall survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75 years
- •Clinical diagnosis of HCC was confirmed by histopathological examination of surgical samples in all patients
- •Tumor stage fitted into Milan Criteria
- •Patients have Child-Pugh A liver function
- •No previous neoadjuvant treatment
- •No evidence of metastasis to the lymph nodes and/or distant metastases on the basis of preoperative imaging results and perioperative findings
- •No malignancy other than HCC for 5 years prior to the initial HCC treatment
- •No history of encephalopathy, ascites refractory to diuretics or variceal bleeding
排除标准
- •History of cardiac disease:
- •Congestive heart failure > New York Heart Association (NYHA) class 2; active coronary artery disease (myocardial infarction more than 6 months prior to study entry is permitted);
- •Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers, calcium channel blocker or digoxin; or
- •Uncontrolled hypertension (failure of diastolic blood pressure to fall below 90 mmHg, despite the use of 3 antihypertensive drugs).
- •Active clinically serious infections ( > grade 2 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events version 3.0)
- •Known history of human immunodeficiency virus (HIV) infection
- •Known Central Nervous System tumors including metastatic brain disease
- •Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry
- •History of organ allograft
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
- •Known or suspected allergy to the investigational agent or any agent given in association with this trial
- •Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study
- •Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial.
- •Excluded therapies and medications, previous and concomitant:
- •Autologous bone marrow transplant or stem cell rescue within four months of start of study drug
结局指标
主要结局
Overall survivals
时间窗: 5-years
次要结局
- Recurrence rates(5-years)
研究者
Jian-Hong Zhong
Affiliated Tumor Hospital
Guangxi Medical University
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan CriteriaHepatocellular CarcinomaNCT01570075Sun Yat-sen University180
Unknown
3 期
RFA vs. SBRT for Small HCCHepatocellular CarcinomaNCT03898921Sun Yat-sen University270
Unknown
3 期
RFA+Highly-purified CTL vs. RFA Alone for Recurrent HCCHepatocellular CarcinomaNCT02678013Ming Kuang210
Unknown
4 期
Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCCHepatocellular CarcinomaNCT02535117Sun Yat-sen University216
Unknown
3 期
TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular CarcinomaSurgeryAblationHepatocellular CarcinomaNCT01833286Sun Yat-sen University200